Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapastinel in obsessive-compulsive disorder
NCT02267629Phase 2Completed
- Sponsor
- New York State Psychiatric Institute
- Start
- Oct 2014
- Primary completion
- Feb 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of rapastinel in obsessive compulsive disorder (OCD), sponsored by New York State Psychiatric Institute. Primary endpoint: Yale-Brown Obsessive Compulsive Challenge Scale at 230 months. Started Oct 2014; status: completed.
02
Drugs
rapastinel
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT02267629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267629.